Regeneron Pharmaceuticals' Change in Receivables fell 5653.65% to $51.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$498.1 million, marking a year-over-year decrease of 18990.97%. This contributed to the annual value of -$498.1 million for FY2025, which is 18990.97% down from last year.
Per Regeneron Pharmaceuticals' latest filing, its Change in Receivables stood at $51.2 million for Q4 2025, which was down 5653.65% from $80.3 million recorded in Q3 2025.
Over the past 5 years, Regeneron Pharmaceuticals' Change in Receivables peaked at $2.8 billion during Q2 2021, and registered a low of -$1.5 billion during Q3 2021.
Moreover, its 5-year median value for Change in Receivables was $69.3 million (2021), whereas its average is $80.7 million.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Change in Receivables crashed by 215403.09% in 2022, and later skyrocketed by 1820000.0% in 2024.
Regeneron Pharmaceuticals' Change in Receivables (Quarter) stood at $584.5 million in 2021, then tumbled by 137.57% to -$219.6 million in 2022, then surged by 137.66% to $82.7 million in 2023, then soared by 42.44% to $117.8 million in 2024, then plummeted by 56.54% to $51.2 million in 2025.
Its Change in Receivables was $51.2 million in Q4 2025, compared to $80.3 million in Q3 2025 and $28.2 million in Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value